[
  {
    "ts": null,
    "headline": "Trump Says Drug Tariffs Probable by Aug. 1, Downplays More Deals",
    "summary": "(Bloomberg) -- President Donald Trump said he was likely to impose tariffs on pharmaceuticals as soon as the end of the month and that levies on semiconductors could come soon as well, suggesting that those import taxes could hit alongside broad “reciprocal” rates set for implementation on Aug. 1.Most Read from BloombergThe Dutch Intersection Is Coming to Save Your LifeAdvocates Fear US Agents Are Using ‘Wellness Checks’ on Children as a Prelude to ArrestsLA Homelessness Drops for Second YearMan",
    "url": "https://finnhub.io/api/news?id=2e64ed0720018a95139fe7b4de57bba326a5f5f91c3662abe605a43aaea27033",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752621803,
      "headline": "Trump Says Drug Tariffs Probable by Aug. 1, Downplays More Deals",
      "id": 135964684,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- President Donald Trump said he was likely to impose tariffs on pharmaceuticals as soon as the end of the month and that levies on semiconductors could come soon as well, suggesting that those import taxes could hit alongside broad “reciprocal” rates set for implementation on Aug. 1.Most Read from BloombergThe Dutch Intersection Is Coming to Save Your LifeAdvocates Fear US Agents Are Using ‘Wellness Checks’ on Children as a Prelude to ArrestsLA Homelessness Drops for Second YearMan",
      "url": "https://finnhub.io/api/news?id=2e64ed0720018a95139fe7b4de57bba326a5f5f91c3662abe605a43aaea27033"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Dips More Than Broader Market: What You Should Know",
    "summary": "In the most recent trading session, Eli Lilly (LLY) closed at $771.75, indicating a -3.45% shift from the previous trading day.",
    "url": "https://finnhub.io/api/news?id=c7b993e9713b5aaf321731fc03311340c75ccc710dce81b47b5c497b31f7f533",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752615903,
      "headline": "Eli Lilly (LLY) Dips More Than Broader Market: What You Should Know",
      "id": 135964846,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "In the most recent trading session, Eli Lilly (LLY) closed at $771.75, indicating a -3.45% shift from the previous trading day.",
      "url": "https://finnhub.io/api/news?id=c7b993e9713b5aaf321731fc03311340c75ccc710dce81b47b5c497b31f7f533"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Roundup: Market Talk",
    "summary": "Find insight on Novo Nordisk, European drug exports, and more in the latest Market Talks covering Health Care.",
    "url": "https://finnhub.io/api/news?id=a97e4008d8a4810155db1107958bac681aaeb32c6459dd9025baa18488f24d7b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752612720,
      "headline": "Health Care Roundup: Market Talk",
      "id": 135957444,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Find insight on Novo Nordisk, European drug exports, and more in the latest Market Talks covering Health Care.",
      "url": "https://finnhub.io/api/news?id=a97e4008d8a4810155db1107958bac681aaeb32c6459dd9025baa18488f24d7b"
    }
  },
  {
    "ts": null,
    "headline": "Lilly’s Zepbound Faces a Potential Weight-Loss Rival. It’s Made by a Chinese Biotech.",
    "summary": "A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring to U.S. biopharma.",
    "url": "https://finnhub.io/api/news?id=0e15745a1e0fd582fee87595a2b2f4b9b2bb03e91fee78d263adfce61f5e54b6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752601800,
      "headline": "Lilly’s Zepbound Faces a Potential Weight-Loss Rival. It’s Made by a Chinese Biotech.",
      "id": 135964850,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring to U.S. biopharma.",
      "url": "https://finnhub.io/api/news?id=0e15745a1e0fd582fee87595a2b2f4b9b2bb03e91fee78d263adfce61f5e54b6"
    }
  },
  {
    "ts": null,
    "headline": "Connecticut wants to make generic GLP-1s. Will RFK Jr. lend a hand?",
    "summary": "Connecticut is petitioning HHS to ignore GLP-1 patents and allow the state to manufacture generics.",
    "url": "https://finnhub.io/api/news?id=daa263f5dbe6cca0711d189d5aa8a0a3b6e64ec8d39033f008cd4d1835b4ace2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752591419,
      "headline": "Connecticut wants to make generic GLP-1s. Will RFK Jr. lend a hand?",
      "id": 135958240,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Connecticut is petitioning HHS to ignore GLP-1 patents and allow the state to manufacture generics.",
      "url": "https://finnhub.io/api/news?id=daa263f5dbe6cca0711d189d5aa8a0a3b6e64ec8d39033f008cd4d1835b4ace2"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Secures FDA Label Update for Alzheimer’s Disease Treatment",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of Goldman Sachs’ top healthcare stock picks. On July 9, the company confirmed the approval by the US Food and Drug Administration of a label update for its once-monthly amyloid-targeting therapy for adults with early symptomatic Alzheimer’s disease (AD). The new label significantly reduces the incidence of amyloid-related […]",
    "url": "https://finnhub.io/api/news?id=0737c8014f18bb08e95939aa4ceb5f80033b7cbca48f81ad708becfe2bee517a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752585024,
      "headline": "Eli Lilly (LLY) Secures FDA Label Update for Alzheimer’s Disease Treatment",
      "id": 135964853,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of Goldman Sachs’ top healthcare stock picks. On July 9, the company confirmed the approval by the US Food and Drug Administration of a label update for its once-monthly amyloid-targeting therapy for adults with early symptomatic Alzheimer’s disease (AD). The new label significantly reduces the incidence of amyloid-related […]",
      "url": "https://finnhub.io/api/news?id=0737c8014f18bb08e95939aa4ceb5f80033b7cbca48f81ad708becfe2bee517a"
    }
  },
  {
    "ts": null,
    "headline": "Here's How to Play AbbVie Stock as it Reaches Golden Cross",
    "summary": "ABBV hits a bullish golden cross as Skyrizi and Rinvoq drive growth, offsetting Humira losses and aesthetic headwinds.",
    "url": "https://finnhub.io/api/news?id=f28b77868975c7f132bae34484b78583d0475940bc899f3b8a32f85e5e957415",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752582900,
      "headline": "Here's How to Play AbbVie Stock as it Reaches Golden Cross",
      "id": 135962658,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "ABBV hits a bullish golden cross as Skyrizi and Rinvoq drive growth, offsetting Humira losses and aesthetic headwinds.",
      "url": "https://finnhub.io/api/news?id=f28b77868975c7f132bae34484b78583d0475940bc899f3b8a32f85e5e957415"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Plunges 20% YTD: How Should Investors Play the Stock?",
    "summary": "NVO shares fall 19.9% year to date amid weak CagriSema data, CEO exit and rising pressure from rivals in obesity care.",
    "url": "https://finnhub.io/api/news?id=5601753e6705c84146473dc1f83434e4b9cbffe179037df81ac46c3a8241cc62",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752582840,
      "headline": "Novo Nordisk Plunges 20% YTD: How Should Investors Play the Stock?",
      "id": 135959025,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NVO shares fall 19.9% year to date amid weak CagriSema data, CEO exit and rising pressure from rivals in obesity care.",
      "url": "https://finnhub.io/api/news?id=5601753e6705c84146473dc1f83434e4b9cbffe179037df81ac46c3a8241cc62"
    }
  },
  {
    "ts": null,
    "headline": "Health Canada Approves Lilly's Omvoh® (mirikizumab) for Crohn's Disease; New Citrate-Free Formulation",
    "summary": "Eli Lilly Canada Inc. (Lilly Canada) announced today that Health Canada has approved Omvoh® (mirikizumab) for CD, which will soon be available to patients in Canada. Omvoh® is an interleukin-23p19 antagonist for the treatment of adult patients with moderately to severely active CD who have had an inadequate response, loss of response, or were intolerant to either conventional therapy or a biologic treatment.1 Health Canada has also approved a new citrate-free formulation of Omvoh® for subcutaneo",
    "url": "https://finnhub.io/api/news?id=d0fcdf35f9570a97ddce5bf8c409751d9b6d1285c40edaeefabec8f8db9a8310",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752582600,
      "headline": "Health Canada Approves Lilly's Omvoh® (mirikizumab) for Crohn's Disease; New Citrate-Free Formulation",
      "id": 135964858,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly Canada Inc. (Lilly Canada) announced today that Health Canada has approved Omvoh® (mirikizumab) for CD, which will soon be available to patients in Canada. Omvoh® is an interleukin-23p19 antagonist for the treatment of adult patients with moderately to severely active CD who have had an inadequate response, loss of response, or were intolerant to either conventional therapy or a biologic treatment.1 Health Canada has also approved a new citrate-free formulation of Omvoh® for subcutaneo",
      "url": "https://finnhub.io/api/news?id=d0fcdf35f9570a97ddce5bf8c409751d9b6d1285c40edaeefabec8f8db9a8310"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: Still Too Pricey To Buy",
    "summary": "Eli Lilly's weight loss drugs boost revenue, but high valuation limits upside. Explore their GLP-1 success, pipeline potential, and investment outlook.",
    "url": "https://finnhub.io/api/news?id=05d729e083f64accb3840aebcae273ce8576afc8168e7315817efbc3122de4aa",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752578154,
      "headline": "Eli Lilly: Still Too Pricey To Buy",
      "id": 135947240,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2189405678/image_2189405678.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly's weight loss drugs boost revenue, but high valuation limits upside. Explore their GLP-1 success, pipeline potential, and investment outlook.",
      "url": "https://finnhub.io/api/news?id=05d729e083f64accb3840aebcae273ce8576afc8168e7315817efbc3122de4aa"
    }
  },
  {
    "ts": null,
    "headline": "Parnassus Growth Equity Fund Q2 2025 Commentary",
    "summary": "Parnassus Growth Equity Fund (Investor Shares) returned 18.97% (net of fees) during the quarter, outperforming the Russell 1000 Growth Indexâs 17.84%. Read more here.",
    "url": "https://finnhub.io/api/news?id=76cb4babf97141731cff29a2d4e1fa66167489bdd2866cdffbd4540e8483e33e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752567720,
      "headline": "Parnassus Growth Equity Fund Q2 2025 Commentary",
      "id": 135943109,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2182036952/image_2182036952.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Parnassus Growth Equity Fund (Investor Shares) returned 18.97% (net of fees) during the quarter, outperforming the Russell 1000 Growth Indexâs 17.84%. Read more here.",
      "url": "https://finnhub.io/api/news?id=76cb4babf97141731cff29a2d4e1fa66167489bdd2866cdffbd4540e8483e33e"
    }
  },
  {
    "ts": null,
    "headline": "Amgen: Great Starting Yield For This Wealth Compounder",
    "summary": "Amgen combines patent protection, a robust pipeline, and strong execution for defensive investment.",
    "url": "https://finnhub.io/api/news?id=43424ea61b871b3eb0aef6fd5619c80550422fec595c0c4b232b73874992cca5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752566400,
      "headline": "Amgen: Great Starting Yield For This Wealth Compounder",
      "id": 135942663,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1126636461/image_1126636461.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Amgen combines patent protection, a robust pipeline, and strong execution for defensive investment.",
      "url": "https://finnhub.io/api/news?id=43424ea61b871b3eb0aef6fd5619c80550422fec595c0c4b232b73874992cca5"
    }
  },
  {
    "ts": null,
    "headline": "Kailera touts late-stage win for weight-loss drug in China",
    "summary": "U.S.-based Kailera Therapeutics andChinese firm Jiangsu Hengrui Pharmaceuticals'experimental weight-loss drug has helped overweight patientslose up to 17.7% of body weight in a late-stage study in...",
    "url": "https://finnhub.io/api/news?id=63d334cd2999b244a64d4493f7a04ba77d7b5ca8e9c3aa95d17724ab81da4605",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752564679,
      "headline": "Kailera touts late-stage win for weight-loss drug in China",
      "id": 135941805,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "U.S.-based Kailera Therapeutics andChinese firm Jiangsu Hengrui Pharmaceuticals'experimental weight-loss drug has helped overweight patientslose up to 17.7% of body weight in a late-stage study in...",
      "url": "https://finnhub.io/api/news?id=63d334cd2999b244a64d4493f7a04ba77d7b5ca8e9c3aa95d17724ab81da4605"
    }
  },
  {
    "ts": null,
    "headline": "Parnassus Core Select ETF Q2 2025 Commentary",
    "summary": "Parnassus Core Select ETF Q2 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=b11e555843406bfb556368f689c60a477ec9e713f72e0167ce56ad0cf338eed3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752562440,
      "headline": "Parnassus Core Select ETF Q2 2025 Commentary",
      "id": 135941265,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=b11e555843406bfb556368f689c60a477ec9e713f72e0167ce56ad0cf338eed3"
    }
  }
]